Earnings Call
May 6, 2026
Q1 FY2026
EPS Estimate
2.18
EPS Actual
2.57
Post-Earnings Close
$86.86
Earnings Reaction
+7.6%
CVS Health's first quarter 2026 results came in materially ahead of expectations across nearly every dimension, with adjusted EPS of $2.57 beating the $2.21 consensus estimate by roughly 16% and revenue crossing $100 billion for the quarter, a 6%-plus year-over-year increase. The strength was broad-based, but the headline story is the continued rehabilitation of the Aetna Health Care Benefits segment, which generated approximately $3 billion in adjusted operating income at an 84.6% medical benefit ratio. That MBR improvement reflects both favorable prior-year development in the government book and genuine core outperformance from disciplined medical cost management, a combination that drove over $1 billion of year-over-year AOI improvement at Aetna in a single quarter. Management was sufficiently confident in the trajectory to raise full-year adjusted EPS guidance by $0.30 to a range of $7.30 to $7.50, with total revenue guidance lifted to at least $405 billion and operating cash flow guidance to at least $9.5 billion.
Report generated on May 8, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full CVS analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.